We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diagnostic Tool Predicts Bronchiolitis Obliterans Syndrome

By LabMedica International staff writers
Posted on 11 Jan 2011
A new diagnostic tool, which predicts bronchiolitis obliterans syndrome (BOS) in lung transplant patients, will allow doctors to intervene earlier and, ultimately, to provide life-saving treatments.

BOS is the leading cause of death for those who survive one year after lung transplantation; more than half of recipients will develop BOS within five years. More...
There is currently no cure.

Vibha Lama, MD, MS, assistant professor of pulmonary and critical care medicine at the University of Michigan (U-M) Medical School (Ann Arbor, MI, USA), led a team of U-M investigators who recently discovered that patients who had a high number of stem cells in their lungs six months after transplantation were much more likely to develop BOS than those with lower counts.

The exact relationship between mesenchymal stromal cells and BOS remains unclear but doctors know that most of the cells originate with the donor and not the recipient. Spikes in cell counts are seen shortly after transplantation as the body responds to the injury; those levels usually taper off, but a second rise of cell counts after about six months is linked to a patient's likelihood of developing BOS.

A lung transplant can mean a new chance at life. But many who receive one develop a debilitating, fatal condition that causes scar tissue to build up in the lungs and chokes off the ability to breathe.

"Our study provides the first indication of the important role these cells play in both human repair and disease," Dr. Lama said. "It's very important from the clinical perspective because we didn't previously have any strong biomarkers for BOS."

The translational study also highlighted the importance of the lab-to-bedside cooperation of basic and clinical research, Dr. Lama noted. Having the biomarker will also allow scientists to readily identify a population of patients ideal for testing new drug interventions and therapies.

The findings were published online ahead of print publication in the American Journal of Respiratory and Critical Care Medicine.

Related Links:
University of Michigan Medical School



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.